Genmab — November 2013
-
Det er en forbavsende styrke GEN viser i dag. Mon vi har vendt faldet ryggen og går ind i en ny fase nu?
-
Complement Activations through IgG Hexamers
Complement activation by antibodies represents a potent form of immune defense. By using cryo-electron tomography and mutagenesis studies we reveal the molecular mechanism by which antibody complexed to antigen triggers complement activation. Our data provide a model for understanding complement activation by antibodies and provides leads for its modulation.
Janine Schuurman, Ph.D., Director, Strategic Research, Genmab B.V., The Netherlands -
Muligvis gammelt nyt. Der er så meget pt...http://www.ibclifesciences.com/AntibodyEng/agenda.xml
-
Carnegie har en rigtig god pointe omkring Genmab. med over 30+% af patienter med Gazyva der har grade 3´+ infusion eller neutropenia events vil en meget stor del af de patienter nok stoppe med Gazyva og gå Arzerra eller Rituxan
-
Så selv hvis Gazyva bliver lægernes første valg, vil en stor af patienterne nok indse at de ikke kan tåle Gazyva og skifte behandling ?
-
I patienter uden NOTCH1 mutation er PFS 23,3 for OC kombinationen https://ash.confex.com/ash/2013/webprogram/Paper58266.html
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind